Catalysts for Tianjin Medical University Cancer Institute and Hospital
2 tracked
Apr 28, 2026
phase 2 completion
Tianjin Medical University Cancer Institute and Hospital — AG [gemcitabine + nab-paclitaxel] (Phase II Trial Completion)
AG [gemcitabine + nab-paclitaxel]
→
Apr 25, 2026
phase 2 completion
Tianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)
Efudex
→